Variety of eligible clients: CDEC discussed the uncertainty in the amount of sufferers with reasonably significant to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical specialists consulted by CADTH indicated that some sufferers who are classified as getting delicate or average condition might have a critical bleeding